Results 221 to 230 of about 36,124 (280)

Metastatic Odyssey: Decoding the Genomic Journey from Primary Colorectal Cancer to Disseminated Disease. [PDF]

Cancers (Basel)
Nikolouzakis TK, Souglakos J, Kantidakis EE, Achilleos K, van Staden T, Chrysos E.   +5 more
europepmc   +1 more source

Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer. [PDF]

Nat Commun
Müller DC, Murtha AJ, Bacon JVW, Stephenson M, Wells C, Vasquez-Rios C, Rostin K, Rebane L, Schönlau E, Nikkola J, Alimohamed N, Basappa NS, Finch D, Ko JJ, Lavoie JM, Nappi L, Noonan K, Ong M, Ozgun G, Parimi S, Soleimani M, Sridhar SS, Toren P, Winquist E, Bernales CQ, Koudjanian M, Atwal J, Fung E, Khan L, Eigl B, Othman D, Bismar TA, Wang G, Merza R, Papadakis AI, Spatz A, Kollmannsberger C, Maurice-Dror C, Annala M, Chi KN, Vandekerkhove G, Wyatt AW, Eigl BJ.   +42 more
europepmc   +1 more source

Is There an Ace Up One's Sleeve in the Preanalytical Phase of the Circulating Tumor DNA Analysis? [PDF]

Biofactors
de Azevedo Junior JC, Carneiro DRDC, da Silva FJ, Belicha ABL, Rodrigues ACL, Barra WF, Leal A, Calcagno DQ.   +7 more
europepmc   +1 more source

Design and evaluation of a custom circulating tumour DNA assay to detect endometrial cancer recurrence. [PDF]

NPJ Precis Oncol
Wadsley M, Guttery DS, Cowley C, Donaldson G, Moreman C, Hew R, Stannard E, Zhang L, Collins A, Shaw J, El M.   +10 more
europepmc   +1 more source

ctDNA guiding adjuvant immunotherapy in urothelial carcinoma

Nature, 2021
Minimally invasive approaches to detect residual disease after surgery are needed to identify patients with cancer who are at risk for metastatic relapse. Circulating tumour DNA (ctDNA) holds promise as a biomarker for molecular residual disease and relapse1.
Thomas Powles, Himanshu Sethi, Romain Banchereau   +2 more
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

BRAF-mutant ctDNA predicts outcomes

Nature Reviews Clinical Oncology, 2021
exaly   +3 more sources

ctDNA: Moving toward Clinical Utility

Cancer Discovery, 2022
Abstract Findings from the phase II DYNAMIC study suggest that circulating tumor DNA analyses could help clinicians decide whether patients with stage II colon cancer require chemotherapy after standard surgery. Liquid biopsies could also shed light on the development of resistance to KRASG12C inhibition, paving the way for better ...
openaire   +2 more sources